Objective Gastric cancer is a major gastrointestinal malignancy for which targeted therapies
are emerging as treatment options. This study sought to identify the most prevalent …

The receptor tyrosine kinase c-MET and its ligand, hepatocyte growth factor (HGF), regulate
multiple cellular processes that stimulate cell proliferation, invasion and angiogenesis. This …

Summary Background Tivantinib (ARQ 197), a selective, oral MET inhibitor, improved
overall survival and progression-free survival compared with placebo in a randomised …

Purpose Cabozantinib (XL184) is an orally bioavailable tyrosine kinase inhibitor with activity
against MET and vascular endothelial growth factor receptor 2. We evaluated the activity of …

Summary Background Tivantinib (ARQ 197), a selective oral inhibitor of MET, has shown
promising antitumour activity in hepatocellular carcinoma as monotherapy and in …

The hepatocyte growth factor (HGF) and its receptor, the transmembrane tyrosine kinase
cMET, promote cell proliferation, survival, motility, and invasion as well as morphogenic …

The MET pathway is dysregulated in many human cancers and promotes tumour growth,
invasion and dissemination. Abnormalities in MET signalling have been reported to …

Abstract c-Met is a receptor tyrosine kinase that upon binding of its ligand, hepatocyte
growth factor (HGF), activates downstream pathways with diverse cellular functions that are …

The Met receptor tyrosine kinase (RTK) is an attractive oncology therapeutic target. Met and
its ligand, HGF, play a central role in signaling pathways that are exploited during the …

Abstract The N-methyl-N′-nitroso-guanidine human osteosarcoma transforming gene
(MET) receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) control cellular …